We need to realise that although this is great news, the market here has been expecting it for some time. Thus it is not surprising to have a market response here at the lower end of our expectations. The real benefit in the announcement is that it will help to convince prospective investors and market analysts that psd is a good investment.
Who is going to want other BrachyTherapy treatments now? PSD's BrachySil no doubt will put them all out of business and take the US$1b p.a. expected to be spent on such treatments.
This company is certainly undervalued and it should not be difficult for Gavin and Martin E Janis & Co to convince major investors and market analysts of this.
PSD
psivida limited
